New center’s aim: to ID biomarkers of neurodegenerative diseases (Links to an external site)

Nicolas Barthélemy, PhD, an assistant professor of neurology at Washington University School of Medicine in St. Louis, loads a sample into a mass spectrometer. Barthélemy uses mass spectrometry as part of his work at the university’s new Tracy Family SILQ Center for Neurodegenerative Biology. The center was established to help researchers discover, study and validate biomarkers of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, with a goal of identifying new drug targets and creating better diagnostic and prognostic tests.

A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer’s disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome […]

Consortium to investigate role of neurofilament light chain in neurodegenerative diseases (Links to an external site)

Clinical scientists at Washington University School of Medicine in St. Louis and University College London are collaborating with pharmaceutical companies AbbVie, Biogen, Bristol Myers Squibb and Roche to investigate the role of neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease.

Alzheimer’s protein in blood indicates early brain changes (Links to an external site)

Two decades or more before symptoms arise, plaques of a sticky protein called amyloid begin forming in the brains of people later diagnosed with Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have shown that levels of a specific protein in the blood rise as amyloid plaques form in the brain. […]